Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rokitamycin
- Development stage
- Phase 4
- Lead developer
- Taisho Pharmaceutical
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Rokitamycin is a macrolide antibiotic synthesized from strains of *Streptomyces kitasatoensis*. It is primarily active against Gram-positive bacteria and functions by inhibiting bacterial protein synthesis through specific binding to the 50S subunit of the ribosome, thereby blocking translation in susceptible organisms. This mechanism confers selectivity for prokaryotes due to the absence of 50S ribosomes in eukaryotic cells. Rokitamycin has been used mainly for respiratory tract infections and is considered well-tolerated with a low incidence of adverse reactions[3][4][5][7].
- Brand names
- Rokitamycin
- Other names
- RicamycinRokitamicinaRokitamycine
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on rokitamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rokitamycin.